Lineage Cell Therapeutics (LCTX) Return on Capital Employed (2011 - 2026)

Lineage Cell Therapeutics has reported Return on Capital Employed for 16 years, with the latest figure at 14.95% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed rose 650.0% year-over-year to 14.95%; the trailing twelve-month figure through Mar 2026 stood at 14.95% (up 650.0% YoY), and the FY2025 full-year result was 14.08%, up 898.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 14.95%, up from 15.93% in the prior quarter.
• The five-year high for Return on Capital Employed was 14.95% in Q1 2026, with the low at 43.52% in Q3 2025.
• Historically, Return on Capital Employed has averaged 28.26% across 5 years, with a median of 26.88% in 2023.
• The largest YoY upside for Return on Capital Employed was 2576 bps in 2022 against a maximum downside of 1824 bps in 2022.
• Lineage Cell Therapeutics' Return on Capital Employed stood at 20.77% in 2022, then plunged by 39 bps to 28.88% in 2023, then rose by 18 bps to 23.62% in 2024, then soared by 33 bps to 15.93% in 2025, then grew by 6 bps to 14.95% in 2026.
• The last three Return on Capital Employed figures came in at 14.95% (Q1 2026), 15.93% (Q4 2025), and 43.52% (Q3 2025), per Business Quant data.